GlassScriptPhysician profile
Krisandra Banet
NPI 1043849391
$6,315.25
in general payments reported to CMS, 2019-2025
27 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $1,316 · 2023: $336 · 2024: $2,441 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,314 · Consulting Fee: $1,063 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,314.30 |
| Consulting Fee | $1,062.50 |
| Education | $207.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,168.00 | 2022-2025 | Tremfya |
| Abbvie INC. | $1,671.84 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $268.86 | 2021-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $265.44 | 2021-2025 | Ebglyss, Olumiant, Taltz |
| Amgen INC. | $215.23 | 2021-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $210.77 | 2022-2025 | |
| Ucb, INC. | $196.96 | 2025 | Bimzelx |
| Genzyme Corporation | $196.57 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $193.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $115.34 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $102.25 | 2024-2025 | Sotyktu |
| Journey Medical Corporation | $101.85 | 2021 | |
| Mayne Pharma Commercial LLC | $85.70 | 2025 | |
| Galderma Laboratories, L.P. | $84.32 | 2024-2025 | Aklief |
| Biofrontera INC. | $81.29 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.84 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $57.54 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.86 | 2024 | Spevigo |
| Almirall LLC | $42.21 | 2021-2025 | Seysara, Klisyri |
| Incyte Corporation | $33.94 | 2024 | Opzelura |
| Dermavant Sciences, INC. | $27.58 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.91 | 2025 | Cabtreo |
| Lnhc, INC | $15.09 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $14.97 | 2022 | |
| Verrica Pharmaceuticals INC. | $14.15 | 2024 | Ycanth |
| Organon LLC | $13.59 | 2025 | |
| Genentech USA, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krisandra Banet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.